Shire Board of Directors
Appointed: September 1, 2011
Committee membership: Nomination Committee
Susan served as an independent Non-Executive Director prior to her appointment as Chairman on April 29, 2014.
Skills & experience: Susan brings to her role extensive M&A and finance experience having enjoyed a distinguished global career in investment banking. She held senior positions with The First Boston Corporation, Bankers Trust, Barclays de Zoete Wedd and most recently Credit Suisse where she was Chairman of the EMEA Mergers & Acquisitions team until 2009 and a part-time senior advisor until 2014. Susan is also a former Director of Hong Kong listed global skin care company, L’Occitane International S.A. She holds a BA in Economics and a MBA.
Key appointments: BBA Aviation plc (Non-Executive Director), Coca-Cola HBC AG (Non-Executive Director) and Keurig Green Mountain, Inc. (Non‑Executive Director).
Dr. Flemming Ornskov
Chief Executive Officer
Appointed: January 2, 2013
Committee Chairmanship: Executive Committee
Flemming served as Chief Executive Officer Designate prior to his appointment as Chief Executive Officer on April 30, 2013.
Skills & experience: Flemming brings to his role his operational and medical knowledge and his extensive international, strategic and operational experience in the pharmaceutical sector. He formerly held the position of Non-Executive Chairman of Evotec AG and was Non-Executive Director of PCI Biotech Holding ASA. From 2010 to 2012 he was Chief Marketing Officer and Global Head, Strategic Marketing for General and Speciality Medicine at Bayer. From 2008 to 2010 Flemming served as Global President, Pharmaceuticals and OTC at Bausch & Lomb, Inc. He also served as Chairman, and later as President and Chief Executive Officer, of Life-Cycle Pharma A/S from 2006 to 2008, and as President and Chief Executive Officer of Ikaria, Inc. from 2005 to 2006. Earlier in his pharmaceutical career Flemming held roles of increasing responsibility at Merck & Co., Inc. and Novartis AG, following a distinguished period spent in hospitals and academic medicine. Flemming received his MD from the University of Copenhagen, MBA from INSEAD and Master of Public Health from Harvard University.
Deputy Chairman and
Senior Independent Non-Executive Director
Appointed: April 5, 2004
Committee Chairmanship: Nomination Committee
Committee membership: Audit, Compliance & Risk Committee
David was appointed Senior Independent Non-Executive Director in July 2007 and Deputy Chairman in June 2008.
Skills & experience: David brings to the Board his extensive knowledge and experience in financial reporting, risk management and internal financial controls. He served on the Board of InterContinental Hotels Group plc until 2014, was Chairman of Premier Foods plc until 2010 and held directorships at Camelot Group plc and HMV Group plc. David retired from Cadbury Schweppes plc in 2004 after serving as Chief Financial Officer since 1995. He worked for the Cadbury Schweppes Group between 1965 and 1984 and rejoined the company in 1989 following its acquisition of the Trebor Group, where he was Financial Director. David is a Fellow of the Chartered Institute of Management Accountants.
Key appointments: Flybe Group plc (Non-Executive Director).
Non Executive Director
Appointed: January 1, 2014
Committee Chairmanship: Audit, Compliance & Risk Committee
Skills & experience: Dominic brings to the Board his strategic and financial experience. He holds the position of Group Finance Director at Compass Group PLC, having held the positions of Chief Financial Officer at Iglo Foods Group and European Finance & Strategy Director, Corporate Finance Director, and Group Financial Controller at Cadbury plc. Earlier in his career Dominic worked at PricewaterhouseCoopers where he advised pharmaceutical sector clients.
Key appointments: Compass Group PLC (Group Finance Director).
Appointed: March 15, 2010
Committee membership: Remuneration Committee, Nomination Committee and Science & Technology Committee
Skills & experience: William “Bill” brings to the Board extensive international R&D, commercial, business development and operational experience in the pharmaceutical sector. He worked for Roche from 1986 until 2009; most recently holding the position of CEO of their pharmaceuticals division and serving as a member of the Roche Group Corporate Executive Committee. Bill holds a BA (Hons).
Key appointments: Masters Pharmaceuticals (Chairman), Biotie Therapies Corp. (Chairman), Mesoblast Limited (Non-Executive Director), Vestergaard Frandsen (Vice Chairman), Wellcome Trust (Committee Chairman), Institute of Cancer Research (Trustee) and University of Cologne/Bonn Center for Integrated Oncology (Scientific Advisory Board Member).
Dr. Steven Gillis
Appointed: October 1, 2012
Committee membership: Audit, Compliance & Risk Committee (Interim), Remuneration Committee and Science & Technology Committee
Skills & experience: Steven brings to the Board his extensive technical and scientific knowledge and commercial experience. He is currently a Managing Director at ARCH Venture Partners; a provider of venture capital for technology firms. Prior to this Steven was a founder and Director of Corixa Corporation, acquired by GlaxoSmithKline in 2005, and before that a founder and Director of Immunex Corporation. An immunologist by training Steven has authored more than 300 peer-reviewed publications in the areas of molecular and tumor immunology. He is credited as being a pioneer in the field of cytokines and cytokine receptors, directing the development of multiple marketed products including Leukine, (GM-CSF), Prokine (IL-2) and Enbrel (soluble TNF receptor-Fc fusion protein) as well as the regulatory approval of Bexxar (radiolabeled anti-CD20) and the novel vaccine adjuvant, MPL. Steven received his BA from Williams College and his Ph.D. from Dartmouth College.
Key appointments: ARCH Venture Partners (Managing Director), bluebird bio, Inc. (Non-Executive Director) and VBI Vaccines Inc. (Chairman and Non-Executive Director).
Dr. David Ginsburg
Appointed: June 16, 2010
Committee Chairmanship: Science & Technology Committee
Skills & experience: David brings to the Board his clinical medical experience in internal medicine, hematology-oncology and medical genetics, as well as his extensive basic biomedical laboratory research expertise. David obtained his BA at Yale University, MD at Duke University and completed his medical and research training at Harvard Medical School. David is the recipient of numerous honors and awards, including election to membership in the National Academy of Sciences, the Institute of Medicine and the American Academy of Arts and Sciences.
Key appointments: University of Michigan (James V. Neel Distinguished University Professor of Internal Medicine, Human Genetics and Pediatrics) and Howard Hughes Medical Institute (Investigator).
Appointed: June 16, 2010
Committee Chairmanship: Remuneration Committee
Committee membership: Nomination Committee
Skills & experience: Anne brings to the Board her extensive legal, commercial and remuneration experience. She held the position of Group Director, Human Resources at Centrica plc from 2002 to 2011 and was a member of the Centrica Executive Committee. Her extensive business career includes senior management roles at Shell UK, the position of Deputy Director-General of the Engineering Employers’ Federation and the position of Group Director Human Resources at Smiths Group plc. She is also a former Director of Northumbrian Water plc and SITA UK. Anne holds a Law degree and a postgraduate diploma in Human Resources, and is a qualified lawyer. She is also a Fellow of the Chartered Institute of Personnel & Development, the Royal Society of Arts and the London City and Guilds, and is a member of the Law Society of Scotland.
Key appointments: Tate & Lyle PLC (Non-Executive Director), ExlService Holdings, Inc. (Non-Executive Director), University of Aberdeen Development Trust (Vice Chairman and Trustee) and University of Aberdeen Alumni Fund (Patron).
Appointed: October 31, 2009
Committee membership: Audit, Compliance & Risk Committee and Remuneration Committee
Skills & experience: David brings to the Board extensive international sales, marketing, operational and supply chain experience gained in the pharmaceutical sector. He is due to step down from the Board on April 28, 2015. David was President, Pharmaceutical Operations at GlaxoSmithKline, where he was responsible for the company’s global pharmaceutical operations from 2003 to 2008. Prior to that he was President of GlaxoSmithKline’s US pharmaceuticals business and before that SmithKline Beecham’s North-American pharmaceuticals business. Before joining SmithKline Beecham, David worked for many years at Schering-Plough. He is also a former Director of Allos Therapeutics, Inc. and holds a BA in Biology.
Key appointments: Jabil Circuit, Inc. (Non-Executive Director) and Airgas, Inc. (Non-Executive Director).